Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 March 2004Website:
http://www.cyclacel.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:59:30 GMTDividend
Analysts recommendations
Institutional Ownership
CYCC Latest News
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) held its Q1 2024 Earnings Call on May 14, 2024 at 4:30 PM ET. Present on the call were Grace Kim - Investor Relations, Spiro Rombotis - President and CEO, Brian Schwartz - Chief Medical Officer, and Paul McBarron - Executive Vice President of Finance & COO. The conference call began with a welcome from the operator and all participants were in a listen-only mode.
Cyclacel Pharmaceuticals' stock is surging today following the company's decision to withdraw a public offering that was initially filed in March, as reported in an SEC filing.
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024.
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is falling on Tuesday but it's not due to any negative news from the clinical-stage biopharmaceutical company. Instead, shares of CYCC stock are retreating after undergoing a rally on Monday.
BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Spiro Rombotis, President & Chief Executive Officer, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California.
MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.
What type of business is Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
What sector is Cyclacel Pharmaceuticals in?
Cyclacel Pharmaceuticals is in the Healthcare sector
What industry is Cyclacel Pharmaceuticals in?
Cyclacel Pharmaceuticals is in the Biotechnology industry
What country is Cyclacel Pharmaceuticals from?
Cyclacel Pharmaceuticals is headquartered in United States
When did Cyclacel Pharmaceuticals go public?
Cyclacel Pharmaceuticals initial public offering (IPO) was on 16 March 2004
What is Cyclacel Pharmaceuticals website?
https://www.cyclacel.com
Is Cyclacel Pharmaceuticals in the S&P 500?
No, Cyclacel Pharmaceuticals is not included in the S&P 500 index
Is Cyclacel Pharmaceuticals in the NASDAQ 100?
No, Cyclacel Pharmaceuticals is not included in the NASDAQ 100 index
Is Cyclacel Pharmaceuticals in the Dow Jones?
No, Cyclacel Pharmaceuticals is not included in the Dow Jones index
When does Cyclacel Pharmaceuticals report earnings?
The next expected earnings date for Cyclacel Pharmaceuticals is 09 August 2024